Infection Risk and Safety of Corticosteroid Use

Rheumatic Disease Clinics of North America

Volumn 42, Issue 1, 2016, Pages 157-176

  Youssef, Jameel ^a   Novosad, Shannon A ^a   Winthrop, Kevin L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bacterial infections; Corticosteroids; Opportunistic infections; Rheumatic diseases

Indexed keywords

BCG VACCINE; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; FUNGUS VACCINE; VARICELLA ZOSTER VACCINE; GLUCOCORTICOID; VACCINE;

DRUG EFFICACY; DRUG SAFETY; DRUG USE; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; INFECTION RISK; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STRONGYLOIDIASIS; TUBERCULOSIS; BACTERIAL INFECTION; CHEMICALLY INDUCED; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MASS SCREENING; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; RHEUMATIC DISEASES;

ADRENAL CORTEX HORMONES; BACTERIAL INFECTIONS; GLUCOCORTICOIDS; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; MASS SCREENING; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; RHEUMATIC DISEASES; TUBERCULOSIS; VACCINES;

EID: 84961239050     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.08.004     Document Type: Review

References (88)

1. Svensson B., Boonen A., Albertsson K., et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005, 52(11):3360-3370.
2. Wassenberg S., Rau R., Steinfeld P., et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52(11):3371-3380.
3. Duru N., van der Goes M.C., Jacobs J.W., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013, 72(12):1905-1913.
4. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990, 112(5):352-364.
5. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009, 15(5):469-474.
6. Kersey J.P., Broadway D.C. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006, 20(4):407-416.
7. Walker B.R. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007, 157(5):545-559.
8. Powell C., Chang C., Naguwa S.M., et al. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev 2010, 9(11):721-743.
9. Weinstein R.S. Glucocorticoid-induced osteonecrosis. Endocrine 2012, 41(2):183-190.
10. McEwen B.S., Biron C.A., Brunson K.W., et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev 1997, 23(1-2):79-133.
11. Boumpas D.T., Chrousos G.P., Wilder R.L., et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119(12):1198-1208.
12. Coutinho A.E., Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011, 335(1):2-13.
13. Purton J.F., Monk J.A., Liddicoat D.R., et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 2004, 173(6):3816-3824.
14. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008, 35(3):387-393.
15. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46(9):2287-2293.
16. Goldenberg D.L. Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum 1989, 32(4):496-502.
17. Bermas B.L., Petri M., Goldman D., et al. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 1994, 14(3):169-177.
18. Marquart H.V., Svendsen A., Rasmussen J.M., et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995, 101(1):60-65.
19. Tektonidou M.G., Wang Z., Dasgupta A., et al. Burden of serious infections in adults with systemic lupus erythematosus. A national population-based study, 1996-2011. Arthritis Care Res (Hoboken) 2015, 67(8):1078-1085.
20. Dixon W.G., Suissa S., Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011, 13(4):R139.
21. Capell H.A., Madhok R., Hunter J.A., et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004, 63(7):797-803.
22. Choy E.H., Smith C.M., Farewell V., CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008, 67(5):656-663.
23. Durez P., Malghem J., Nzeusseu Toukap A., et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007, 56(12):3919-3927.
24. Gerlag D.M., Haringman J.J., Smeets T.J., et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004, 50(12):3783-3791.
25. Kirwan J.R., Hallgren R., Mielants H., et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004, 63(6):688-695.
26. Sheldon P. Ileum-targeted steroid therapy in rheumatoid arthritis: double-blind, placebo-controlled trial of controlled-release budesonide. Rheumatol Int 2003, 23(4):154-158.
27. van Everdingen A.A., Jacobs J.W., Siewertsz Van Reesema D.R., et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002, 136(1):1-12.
28. Buttgereit F., Mehta D., Kirwan J., et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013, 72(2):204-210.
29. Bakker M.F., Jacobs J.W., Welsing P.M., et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012, 156(5):329-339.
30. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306(21):2331-2339.
31. Dixon W.G., Abrahamowicz M., Beauchamp M.E., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71(7):1128-1133.
32. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54(2):628-634.
33. Schneeweiss S., Setoguchi S., Weinblatt M.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56(6):1754-1764.
34. Widdifield J., Bernatsky S., Paterson J.M., et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65(3):353-361.
35. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56(4):1125-1133.
36. Strangfeld A., Eveslage M., Schneider M., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011, 70(11):1914-1920.
37. Franklin J., Lunt M., Bunn D., et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007, 66(3):308-312.
38. Greenberg J.D., Reed G., Kremer J.M., CORRONA Investigators, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69(2):380-386.
39. Xie W.L., Li Z.L., Xu Z., et al. The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai. ISRN Rheumatol 2012, 2012:215692.
40. van Dartel S.A., Fransen J., Kievit W., et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the dutch rheumatoid arthritis monitoring (DREAM) registry. Rheumatology (Oxford) 2013, 52(6):1052-1057.
41. Dirac M.A., Horan K.L., Doody D.R., et al. Environment or host?: a case-control study of risk factors for mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012, 186(7):684-691.
42. MacDougall L., Fyfe M., Romney M., et al. Risk factors for cryptococcus gattii infection, british columbia, canada. Emerg Infect Dis 2011, 17(2):193-199.
43. Garnacho-Montero J., Amaya-Villar R., Ortiz-Leyba C., et al. Isolation of aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005, 9(3):R191-R199.
44. Dimopoulos G., Ntziora F., Rachiotis G., et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008, 106(2):523-529.
45. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71(1):5-13.
46. Lertnawapan R., Totemchokchyakarn K., Nantiruj K., et al. Risk factors of pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009, 29(5):491-496.
47. Kermani T.A., Ytterberg S.R., Warrington K.J. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res (Hoboken) 2011, 63(5):761-765.
48. Chew L.C., Maceda-Galang L.M., Tan Y.K., et al. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. J Clin Rheumatol 2015, 21(2):72-75.
49. Mekinian A., Durand-Joly I., Hatron P.Y., et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford) 2011, 50(3):569-577.
50. Fritzsche C., Riebold D., Munk-Hartig A., et al. High prevalence of pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 2012, 41(3):208-213.
51. Jarrousse B., Guillevin L., Bindi P., et al. Increased risk of pneumocystis carinii pneumonia in patients with wegener's granulomatosis. Clin Exp Rheumatol 1993, 11(6):615-621.
52. Kronbichler A., Jayne D.R., Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 2015, 45(3):346-368.
53. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151(3 Pt 1):795-799.
54. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis. Arthritis Rheum 1997, 40(12):2187-2198.
55. Besada E., Nossent J.C. Should pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?. Clin Rheumatol 2013, 32(11):1677-1681.
56. Godeau B., Mainardi J.L., Roudot-Thoraval F., et al. Factors associated with pneumocystis carinii pneumonia in wegener's granulomatosis. Ann Rheum Dis 1995, 54(12):991-994.
57. Veetil B.M., Myasoedova E., Matteson E.L., et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2013, 65(6):854-861.
58. Wolfe F., Michaud K., Chakravarty E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006, 45(11):1370-1375.
59. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301(7):737-744.
60. Winthrop K.L., Baddley J.W., Chen L., et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013, 309(9):887-895.
61. Pappas D.A., Hooper M.M., Kremer J.M., et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying anti-rheumatic drugs. Arthritis Care Res (Hoboken) 2015, [Epub ahead of print].
62. Zisman D., Bitterman H., Shalom G., et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis 2014, [Epub ahead of print].
63. Fardet L., Rybojad M., Gain M., et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009, 145(8):889-893.
64. Buonfrate D., Requena-Mendez A., Angheben A., et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 2013, 13:78.
65. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43(6):717-722.
66. Winthrop K.L., Baxter R., Liu L., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013, 72(1):37-42.
67. Tam L.S., Li E.K., Wong S.M., et al. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in hong kong. Scand J Rheumatol 2002, 31(5):296-300.
68. Ramagopalan S.V., Goldacre R., Skingsley A., et al. Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med 2013, 11:97.
69. Jick S.S., Lieberman E.S., Rahman M.U., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55(1):19-26.
70. Kim H.A., Yoo C.D., Baek H.J., et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998, 16(1):9-13.
71. Brassard P., Lowe A.M., Bernatsky S., et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in quebec, canada. Arthritis Rheum 2009, 61(3):300-304.
72. Katsuyama T., Saito K., Kubo S., et al. Prophylaxis for pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther 2014, 16(1):R43.
73. Mukhtyar C., Guillevin L., Cid M.C., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68(3):310-317.
74. Davis S.A., Krowchuk D.P., Feldman S.R. Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the united states. Southampt Med J 2014, 107(5):292-293.
75. Shingles (Herpes Zoster). Centers for Disease Control and Prevention. 2014. Available at: Accessed June 12, 2015. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm.
76. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
77. Curtis J., Yang S., Chen L., et al. Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination. Ann Rheum Dis 2014, 73(Suppl 2):452.
78. ZOSTAVAX Zoster Vaccine Live Product Information. Available at:. Accessed June 12, 2015. http://MerckVaccines.com.
79. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639.
80. Contraindications and Precautions to Commonly Used Vaccines in Adults. Centers for Disease Control and Prevention. 2015. Available at: Accessed June 12, 2015. http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-contraindications.html.
81. Targeted tuberculin testing and treatment of latent tuberculosis infection. American thoracic society. MMWR Recomm Rep 2000, 49(RR-6):1-51.
82. Kim J.H., Cho S.K., Han M., et al. Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in korean patients with rheumatic diseases. Semin Arthritis Rheum 2013, 42(4):424-432.
83. Arenas Miras Mdel M., Hidalgo-Tenorio C., Jimenez-Gamiz P., et al. Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. Biomed Res Int 2014, 2014:291031.
84. Matulis G., Juni P., Villiger P.M., et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008, 67(1):84-90.
85. Vassilopoulos D., Stamoulis N., Hadziyannis E., et al. Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008, 35(7):1271-1276.
86. Calabrese C., Overman R.A., Dusetzina S.B., et al. Indeterminate QuantiFERON-TB gold in-tube results in patients with chronic inflammatory diseases on immunosuppressive therapy. Arthritis Care Res (Hoboken) 2014, 67(8):1063-1069.
87. Bartalesi F., Vicidomini S., Goletti D., et al. QuantiFERON-TB gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009, 33(3):586-593.
88. Recommended Adult Immunization Schedule-United States - 2015. Centers for Disease Control and Prevention. Available at: Accessed June 12, 2015. http://www.cdc.gov/vaccines/schedules/hcp/adult.html.